

**CANADIAN GENERAL MEDICAL
CENTER COMPLEX COMPANY**
(A Saudi Joint Stock Company)

**INTERIM CONDENSED FINANCIAL
STATEMENTS (UN-AUDITED) FOR THE THREE-
MONTH AND SIX-MONTH PERIODS
ENDED JUNE 30, 2025 AND
INDEPENDENT AUDITOR'S REVIEW REPORT**

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

**INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2025
AND INDEPENDENT AUDITOR'S REVIEW REPORT**

<u>Table of contents</u>	<u>Pages</u>
Independent auditor's review report on the interim condensed financial statements	2
Interim condensed statement of financial position	3
Interim condensed statement of profit or loss and other comprehensive income	4
Interim condensed statement of changes in equity	5
Interim condensed statement of cash flows	6
Notes to the interim condensed financial statements	7 – 12

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE
INTERIM CONDENSED FINANCIAL STATEMENTS**

**The Shareholders of
Canadian General Medical Center Complex Company
(A Saudi Joint Stock Company)**

Introduction

We have reviewed the accompanying interim condensed statement of financial position of Canadian General Medical Center Complex Company - "Saudi Joint Stock Company" ("the Company") as of June 30, 2025, and the related interim condensed statement of profit or loss and other comprehensive income for the three-month and six-month periods then ended, and the interim condensed statements of changes in equity and cash flows for the six-month period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed financial statements in accordance with International Accounting Standard 34 -Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", that is endorsed in the Kingdom of Saudi Arabia. A review of interim condensed financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed financial statements are not prepared in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

For Dr. Mohamed Al-Amri & Co.



Ahmed Al Jumah
Certified Public Accountant
Registration No. 621



Damman, on : 18 Safar 1447 (H)
Corresponding to: 12 August, 2025 G

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2025

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	<u>Notes</u>	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
ASSETS			
Non-current assets			
Property and equipment	4	22,742,917	16,920,881
Right-of-use assets	5	6,654,659	7,288,505
Total non-current assets		29,397,576	24,209,386
Current assets			
Inventories		3,314,574	3,421,737
Trade receivables	6	51,511,054	41,764,529
Prepayments and other receivables		7,211,303	10,745,620
Investment at fair value through profit or loss (FVTPL)	7	36,045,364	35,074,253
Cash and cash equivalents		2,942,159	4,659,967
Total current assets		101,024,454	95,666,106
TOTAL ASSETS		130,422,030	119,875,492
EQUITY AND LIABILITIES			
Equity			
Share capital		77,000,000	77,000,000
Actuarial reserve		(1,347,780)	(856,463)
Retained earnings		22,152,874	17,725,975
Total equity		97,805,094	93,869,512
Liabilities			
Non-current liabilities			
Employees' benefits obligations		7,403,524	6,696,709
Lease liabilities	5	5,156,287	4,744,896
Total non-current liabilities		12,559,811	11,441,605
Current liabilities			
Trade and other payables		15,180,954	8,918,855
Due to related parties	9.C	2,274,571	915,811
Lease liabilities	5	1,538,864	2,570,882
Provision for zakat	8	1,062,736	2,158,827
Total current liabilities		20,057,125	14,564,375
Total liabilities		32,616,936	26,005,980
TOTAL EQUITY AND LIABILITIES		130,422,030	119,875,492

The accompanying notes from 1 to 16 form an integral part of these un-audited interim condensed financial statements.

Finance Manager



CEO



Chairman



CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

**INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED JUNE 30, 2025**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	<u>Note</u>	<u>Three-Month Period Ended</u>		<u>Six-Month Period Ended</u>	
		<u>June 30, 2025</u> <u>(Un-audited)</u>	<u>June</u> <u>30,2024</u> <u>(Un-audited)</u>	<u>June 30,</u> <u>2025</u> <u>(Un-audited)</u>	<u>June 30,2024</u> <u>(Un-audited)</u>
Revenue	10	32,253,331	26,901,643	62,342,504	51,224,437
Cost of revenue		(23,939,207)	(19,769,744)	(45,183,212)	(39,713,972)
Gross profit		8,314,124	7,131,899	17,159,292	11,510,465
General and administrative expenses		(3,964,947)	(2,727,596)	(6,573,046)	(5,374,923)
Selling and marketing expenses		(591,966)	(977,935)	(1,382,721)	(1,839,624)
Expected credit loss / reversal on trade receivables	6	(247,857)	313,774	(507,468)	(417,446)
Operating profit		3,509,354	3,740,142	8,696,057	3,878,472
Fair value changes of investments at FVTPL		(1,960,610)	-	983,453	-
Finance cost		(219,494)	(196,851)	(434,337)	(352,814)
Other income, net		-	507,352	87,709	1,325,668
Profit before Zakat		1,329,250	4,050,643	9,332,882	4,851,326
Zakat	8	(497,694)	(460,110)	(1,055,983)	(1,481,580)
Net profit for the period		831,556	3,590,533	8,276,899	3,369,746
Other comprehensive income					
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>					
Gain / (loss) on remeasurement of employees' benefit obligations		79,552	341,632	(491,317)	(215,641)
Total comprehensive income for the period		911,108	3,932,165	7,785,582	3,154,105
Basic and diluted earnings per share	11	0.01	0.05	0.11	0.04

The accompanying notes from 1 to 16 form an integral part of these un-audited interim condensed financial statements.

Finance Manager



CEO



Chairman



CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	Share capital	Statutory reserve	Actuarial reserve	Retained earnings	Total
For the six-month period ended June 30, 2024					
(un-audited)					
Balance at January 01, 2024	77,000,000	6,758,115	442,016	7,628,729	91,828,860
Net profit for the period	-	-	-	3,369,746	3,369,746
Other comprehensive loss	-	-	(215,641)	-	(215,641)
Total comprehensive income for the period	-	-	(215,641)	3,369,746	3,154,105
Dividend (note 13)	-	-	-	(6,930,000)	(6,930,000)
Transfer to retained earnings	-	(6,758,115)	-	6,758,115	-
Balance at June 30, 2024	77,000,000	-	226,375	10,826,590	88,052,965
For the six-month period ended June 30, 2025					
(un-audited)					
Balance at January 01, 2025	77,000,000	-	(856,463)	17,725,975	93,869,512
Net profit for the period	-	-	-	8,276,899	8,276,899
Other comprehensive loss	-	-	(491,317)	-	(491,317)
Total comprehensive income for the period	-	-	(491,317)	8,276,899	7,785,582
Dividend (note 13)	-	-	-	(3,850,000)	(3,850,000)
Balance at June 30, 2025	77,000,000	-	(1,347,780)	22,152,874	97,805,094

The accompanying notes from 1 to 16 form an integral part of these un-audited interim condensed financial statements.

Finance Manager



CEO



Chairman



CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

INTERIM CONDENSED STATEMENT OF CASH FLOWS**FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025**


(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	For the six-month period ended	
	June 30, 2025	June 30, 2024
	(Un-audited)	(Un-audited)
CASH FLOWS FROM OPERATING ACTIVITIES		
Net profit before zakat	9,332,882	4,851,326
<i>Adjustments for non-cash items:</i>		
Depreciation of property and equipment	1,655,585	993,048
Depreciation on right-of-use assets	1,294,038	768,735
Employees' benefits obligations – provision	740,698	433,408
Finance cost	434,337	352,814
Gain on disposal of property and equipment	(8,696)	(4,400)
Expected credit losses on trade receivables	507,468	417,446
Fair value changes of investment at FVTPL	(983,453)	-
	12,972,859	7,812,377
Changes in working capital		
Inventories	(904,167)	(736,277)
Trade receivables	(10,253,993)	(2,859,372)
Prepayments and other receivables	3,534,317	(3,762,277)
Trade and other payables	6,259,140	6,373,611
Due from a related party	-	(76,558)
Due to related parties	1,358,760	657,029
Cash generated from operations	12,966,916	7,408,533
Employees' benefits obligations paid	(679,672)	(542,547)
Zakat paid	(2,152,074)	(2,645,171)
Net cash generated from operating activities	10,135,170	4,220,815
CASH FLOWS FROM INVESTING ACTIVITIES		
Additions to investments at fair value through profit or loss (FVTPL)	(35,318,854)	-
Proceeds from disposal of investments at fair value through profit or loss (FVTPL)	35,331,196	-
Additions to property and equipment	(6,466,291)	(2,820,773)
Proceeds from disposal of property and equipment	8,696	50,000
Net cash used in investing activities	(6,445,253)	(2,770,773)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividend paid	(3,850,000)	(6,930,000)
Repayment of lease liabilities	(1,557,725)	(2,396,135)
Net cash used in financing activities	(5,407,725)	(9,326,135)
Net change in cash and cash equivalents	(1,717,808)	(7,876,093)
Cash and cash equivalents at beginning of the period	4,659,967	53,360,555
Cash and cash equivalents at end of the period	2,942,159	45,484,462

The significant non-cash transactions are as follows:

Additions to property and equipment transferred from inventory	1,011,330	-
Additions to right-of-use and lease liabilities	660,192	5,411,441

The accompanying notes from 1 to 16 form an integral part of these un-audited interim condensed financial statements.

Finance Manager**CEO****Chairman**

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

1. ORGANIZATION AND ACTIVITY

Canadian General Medical Center Complex Company (the “Company”) is a Saudi joint stock company initially incorporated as a limited liability company registered in Dammam, Kingdom of Saudi Arabia under Commercial Registration No. 2050058605 dated Safar 13, 1429H (corresponding to February 20, 2008).

During the year 2020, the Company increased its share capital in several stages from ﷲ 2 million to ﷲ 77 million in addition to the entry of new shareholders. Later on, the shareholders of the Company decided to convert the Company from a Limited Liability Company to a Saudi Joint Stock Company under the same Commercial Registration. The Company obtained Ministerial approval for the said conversion on Jumada Al-Awwal 15, 1442 H, corresponding to December 30, 2020.

The Capital Market Authority, in its decision issued on Dhu al-Qi’dah 18, 1442 -H (corresponding to June 28, 2021), approved the Company’s request to register its shares for direct listing in the Parallel Market – Nomu.

During the year 2023, the Board of Directors of the Company resolved, in its meeting held on July 6, 2023, to approve the transition of the Company from the parallel market (Nomu) to the main market which is subject to regulatory approvals. The Company has also appointed a financial advisor for the purpose of the said transition.

On July 27, 2025, the Company submitted its application for the transition to the main market through the designated online portal provided by the relevant regulatory authorities.

The main activities of the Company are management of hospitals and health centers and trade in hospital tools and equipment and ambulances under License No. 10045 dated Jumada Al-Awwal 18, 1436 -H (corresponding to March 9, 2015).

The Company's registered office is located at Dammam, Kingdom of Saudi Arabia.

These interim condensed financial statements include the assets, liabilities and financial results of the Company and its following branches:

Branch CR NO.	CR Date (Hijri)	CR Date (Gregorian)	City
2050116858	03/11/1439-H	16/07/2018-G	Dammam
2055026411	22/04/1439-H	09/01/2018-G	Jubail
2059004078	08/06/1438-H	07/03/2017-G	Abqaiq
2051056715	15/05/1435-H	16/03/2014-G	Khobar
1009042659	18/11/1445-H	26/05/2024-G	Riyadh

2. STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION

These interim condensed financial statements have been prepared in accordance with International Accounting Standard 34 - “Interim Financial Reporting” (IAS-34) as endorsed in the Kingdom of Saudi Arabia and other standards and pronouncement that are issued by the Saudi Organization for Chartered and Professional Accountants (“SOCPA”).

These interim condensed financial statements do not include all the information and disclosures required in annual financial statements and therefore, should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2024. In addition, results for the six months period ended June 30, 2025 are not necessarily indicative of the results that may be expected for the financial year ending December 31, 2025.

The significant judgements made by management in applying the Company’s key sources of estimation uncertainty are similar to those described in the Company’s annual financial statements for the year ended December 31, 2024.

These interim condensed financial statements have been presented in Saudi Riyals (“ﷲ”) which is also the functional currency of the Company. All figures have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

3. MATERIAL ACCOUNTING POLICIES

The methods of computation and accounting policies adopted in the preparation of these interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2024, except for the following amendments which applied for the first time in 2025. However, these are either not relevant to the Company’s activities or require accounting which is consistent with the Company’s current accounting policies.

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

3. MATERIAL ACCOUNTING POLICIES (CONTINUED)**3.1 Standards and amendments issued and applied effective in current period**

There are no new standards issued, however, there are amendments to the following standards, which are effective in current period and have no material impact on Company’s interim condensed financial statement;

Amendments to standard	Description	Effective for annual years beginning on or after
IAS 21	Amendments- Lack of Exchangeability	January 1, 2025

3.2 Impact of accounting standards to be effective in future periods

There are a number of standards and interpretations which have been issued by the International Accounting standards Board that are effective for periods beginning subsequent to December 31, 2025 (the date of the Company's next annual financial statements) that the Company has decided not to adopt early. The Company does not believe that these standards and interpretations will have a material impact on its interim condensed financial statements once adopted.

4. PROPERTY AND EQUIPMENT

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Net book value at beginning of period / year	16,920,881	11,010,830
Additions during the period / year	6,466,291	8,030,666
Transfers during the period / year	1,011,330	-
Depreciation charged during the period / year	(1,655,585)	(2,003,037)
Disposals during the period / year	-	(117,578)
Net book value at the end of the period / year	22,742,917	16,920,881

5. RIGHT OF USE ASSETS AND LEASE LIABILITIES**Right of use assets**

The following is a reconciliation of changes in right-of-use assets:

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Net book value at beginning of period / year	7,288,505	3,907,209
Additions during the period / year	698,202	5,411,441
Adjustments during the period / year	(38,010)	-
Depreciation charged during the period / year	(1,294,038)	(2,030,145)
Net book value at the end of the period / year	6,654,659	7,288,505

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

5. RIGHT OF USE ASSETS AND LEASE LIABILITIES (CONTINUED)**Lease liabilities**

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Balance at beginning of period / year	7,315,778	4,379,035
Interest expense during the period / year	278,854	509,102
Additions during the period / year	698,202	5,411,441
Adjustments during the period / year	(39,958)	-
Paid during the period / year	(1,557,725)	(2,983,800)
Balance at the end of the period / year	6,695,151	7,315,778
Less: current portion	(1,538,864)	(2,570,882)
Non-current portion	5,156,287	4,744,896

6. TRADE RECEIVABLES

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Trade receivables	58,689,923	48,435,930
Less: Expected credit loss	(7,178,869)	(6,671,401)
	51,511,054	41,764,529

Receivables include an amount of SR 18.1 million (2024: SR 17.4 million) from a single customer.

Movement of expected credit loss:

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Opening balance	6,671,401	6,293,700
Charged during the period / year	507,468	377,701
Closing balance	7,178,869	6,671,401

7. INVESTMENT AT FAIR VALUE THROUGH PROFIT OR LOSS (FVTPL)

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Opening	35,074,253	-
Additions during the period / year	35,318,854	35,000,000
Fair value changes of investment at FVTPL	983,453	74,253
Disposal during the period / year	(35,331,196)	-
Balance at the end of the period / year	36,045,364	35,074,253

During the year 2024, the Company's management entered into a local Discretionary Portfolio Management ("DPM") agreement managed by the investment manager. The Company has elected to classify such investments at fair value through profit or loss (FVTPL). The value of said investments as at June 30, 2025 amounted to ﷲ 36,045,364 (December 31, 2024: ﷲ35,074,253) including cash amounted to ﷲ 97,335 (December 31, 2024: ﷲ 3,600,000).

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

8. PROVISION FOR ZAKAT**A- Movement of zakat provision**

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Balance at beginning of the period / year	2,158,827	2,178,857
Charged during the period / year	1,055,983	2,158,827
Under provision for prior years	-	466,314
Payments during the period / year	(2,152,074)	(2,645,171)
Balance at the end of the period / year	1,062,736	2,158,827

B- Status of zakat assessment

The Company has submitted its Zakat returns till the year ended December 31, 2024, and obtained the zakat certificate.

9. TRANSACTIONS WITH RELATED PARTIES

9.A It includes entities under common directorship, Board of Directors (executive and non-executive members) and the key management personnel of the Company. The following are the benefits paid or due to key management personnel for their services:

	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
Short-term employee benefits and salaries	1,574,154	1,386,667
End of service benefits	90,622	100,805
	1,664,776	1,487,472

9.B The significant transactions with related parties during the period are as follows:

Related party	Nature of transaction	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
Academy of Learning Company	Services	-	66,572
Khairat Al-Ammariah Real Estate Co.	Leasehold improvements	-	1,202,500
	Leases of building	588,898	1,029,600
	Commission	-	25,740
Mehan for Human Resources	Recruitment services	2,403,966	1,339,603

9.C Due to related parties

	June 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Mehan for Human Resources	1,979,528	915,811
Khairat Al-Ammariah Real Estate Co	295,043	-
	2,274,571	915,811

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)

FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

10. REVENUE

	For the three-month ended		For the six-month ended	
	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
Corporate customers	31,566,489	26,039,246	61,163,757	49,769,532
Individual customers	686,842	862,397	1,178,747	1,454,905
	32,253,331	26,901,643	62,342,504	51,224,437

	For the three-month ended		For the six-month ended	
	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
Cash revenue	688,709	862,397	1,180,700	1,454,905
Credit revenue	31,564,622	26,039,246	61,161,804	49,769,532
	32,253,331	26,901,643	62,342,504	51,224,437

	For the three-month ended		For the six-month ended	
	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
At point in time	5,705,365	1,120,130	7,953,455	1,872,515
Over time	26,547,966	25,781,513	54,389,049	49,351,922
	32,253,331	26,901,643	62,342,504	51,224,437

All revenue is earned inside the Kingdom of Saudi Arabia.

11. EARNINGS PER SHARE

Considering the Company doesn't have any dilutive instruments as of June 30, 2025 and June 30, 2024, dilute earnings per share is the same as basic earnings per share which is as follows:

	For the three-month ended		For the six-month ended	
	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)	June 30, 2025 (Un-audited)	June 30, 2024 (Un-audited)
Net profit for the period	831,556	3,590,533	8,276,899	3,369,746
Weighted average number of ordinary shares	77,000,000	77,000,000	77,000,000	77,000,000
Basic and diluted earnings per share	0.01	0.05	0.11	0.04

12. SEGMENTAL REPORTING

The Company has one segment, which is providing of medical services. The Company operates only in the Kingdom of Saudi Arabia and has no other geographical segment.

Transactions with major customers

The revenue from one of the major customers represent 45% of the total amount of the revenue for the period ended June 30, 2025 (June 30, 2024: 51%).

CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)

FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2025

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

13. DIVIDEND

On March 25, 2024, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 20, 2023, resolved to distribute cash dividend amounted to ﷲ 6,930,000 (ﷲ 0.09 per share) for the second half of the year 2023.

On March 17, 2025, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 24, 2024, resolved to distribute cash dividend amounted to ﷲ 3,850,000 (ﷲ 0.05 per share) for the year 2024 and it was paid on May 25, 2025.

14. MEASUREMENT OF FAIR VALUE

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, on the assumption that market participants act in their economic best interest.

All assets and liabilities that are measured at fair value or whose fair value is disclosed in the interim condensed financial statements are classified according to the scope of the fair value hierarchy shown below:

- Level 1: Quoted (unadjusted) prices quoted in active markets for assets or liabilities that are identical to those being measured.
- Level 2: The inputs that can be observed or monitored for the asset or liability, directly or indirectly, other than the published prices included within the first level.
- Level 3: Inputs that cannot be observed for the asset or liability.

The Company believes that the carrying values of its financial assets and financial liabilities as of June 30, 2025, and June 30, 2024 approximate their fair values because of their short-term nature. The investments measured at fair value through profit or loss represent investments in equity securities traded in active market and are classified at Level 1 of the fair value hierarchy.

15. SIGNIFICANT EVENTS

On June 15, 2025, the Extraordinary General Assembly approved the company's purchase of a number of its own shares, with a maximum of 500,000 shares, for the purpose of allocating them to the Company's employees within the Employee Share Scheme. The purchase will be financed from the Company's own resources. The Board of Directors shall be authorized to complete the purchase within a maximum period of eighteen months from the date of the resolution of the Extraordinary General Assembly. The Company shall retain the purchased shares for a period not exceeding ten years from the date of the Extraordinary General Assembly's approval, as the maximum period for allocation to eligible employees. Upon the expiry of this period, the Company shall follow the procedures and regulations stipulated in the relevant laws and regulations.

16. APPROVAL OF THE INTERIM CONDENSED FINANCIAL STATEMENTS

The interim condensed financial statements were approved by the Board of Directors of the Company on August 07, 2025.